About
Ophthalmic gene therapy built on the AGTC assets. Lead program laru-zova for XLRP (RPGR mutations); VISTA Phase 2/3 enrollment completed Jul 2025, topline data expected 2H 2026. Backed by Syncona (founding investor).
HQ: London/Oxford, UK; Boston, MA; Alachua, FL
Funding
$170M Series B (Jul 2024); >$75M Series C (Jan 2026, Goldman Sachs Alternatives-led)
Series C specifics sourced via aggregator; verify on a primary release.